Guardant Health (NASDAQ: GH) reported Q2 EPS of ($0.48), $0.26 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $177.2 million versus the consensus estimate of $162.59 million.

GUIDANCE:

Guardant Health sees FY2024 revenue of $690-700 million, versus the consensus of $680.2 million.

For earnings history and earnings-related data on Guardant Health (GH) click here.